

S/N 09/700,669

1636
PATENT *lfw*



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Bernt Sweder Van Asbeck et al.	Examiner:	Unknown
Serial No.:	09/700,669	Group Art Unit:	1636
Filed:	November 16, 2000	Docket:	30394-1041
Title:	Use of a Nucleic Acid-Binding Chemotherapeutic Agent, and a Pharmaceutical Composition		

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

In compliance with the duty imposed by 37 C.F.R. § 1.56, and in accordance with 37 C.F.R. §§ 1.97 *et. seq.*, the enclosed materials are brought to the attention of the Examiner for consideration in connection with the above-identified patent application. Applicants respectfully request that this Supplemental Information Disclosure Statement be entered and the documents listed on the attached Form 1449 be considered by the Examiner and made of record. Pursuant to the provisions of MPEP 609, Applicants request that a copy of the 1449 form, initialed as being considered by the Examiner, be returned to the Applicants with the next official communication.

The cited references were made known to the applicant in an office action issued on September 13, 2004, in co-pending application, Serial No. 10/049,579. This Supplemental Information Disclosure Statement is being filed within three months of knowledge of the references cited. Therefore, no fee or certification is required. 37 C.F.R. § 1.97(e).

The Examiner is invited to contact the Applicants' Representative at the below-listed telephone number if there are any questions regarding this communication.

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Serial No :09/700,669

Filing Date: November 16, 2000

Title: Use of a Nucleic Acid-Binding Chemotherapeutic Agent, and a Pharmaceutical Composition

Page 2

Dkt: 30394-1041

Respectfully submitted,

BERNT SWEDER VAN ASBECK ET AL.

By their Representatives,

PEACOCK, MYERS & ADAMS, P.C.


P.O. Box 26927

Albuquerque, New Mexico 87125-6927

Phone 505 998 6130

Date November 22, 2004

By



Stephen A. Slusher

Reg. No. 43,924

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this 22nd day of November, 2004.

Stephen A. Slusher, Reg. No. 43,924

Name



Signature

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)



Complete if Known

Application Number	09/700,669
Filing Date	November 16, 2000
First Named Inventor	Van Asbeck, Bernt
Group Art Unit	1636
Examiner Name	James S. Ketter

Sheet 1 of 1

Attorney Docket No: 30394-1041

US PATENT DOCUMENTS

Examiner Initial *	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
--------------------	---------------------	------------------	---	---

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ²
--------------------	---------------------	------------------	---	---	----------------

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		GOMPELS, MARK M., et al., "Kaposi's Sarcoma in HIV Infection Treated with Vincristine and Bleomycin", <u>AIDS (Long, England), Vol. 6, No. 10, (10/00/1992), 1175-80</u>	
		OHTA, K, et al., "Action of a New Mammalian DNA Polymerase Inhibitor Sulfoquinovosyldiacylglycerol", <u>Biological & Pharmaceutical Bulletin (1999 Feb) Vol. 22, No. 2 pp 111-6 Abstract only.</u>	

EXAMINER**DATE CONSIDERED**

Substitute Disclosure Statement Form (PTO-1449)

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional) ² Applicant is to place a check mark here if English language Translation is attached